期刊论文详细信息
Reviews in Urology
Nocturia: Evaluation and Current Management Strategies
Casey G. Kowalik1  Joshua A. Cohn2  Sophia Delpe3 
[1] Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN;Department of Urology, Einstein Healthcare Network, Philadelphia, PA;Division of Urology, Hospital of the University of Pennsylvania, Philadelphia, PA
关键词: Nocturia;    Benign prostatic hyperplasia;    Overactive bladder;    Nocturnal polyuria;    Desmopressin;   
DOI  :  10.3909/riu0797
学科分类:基础医学
来源: MedReviews, LLC
PDF
【 摘 要 】

Nocturia is a complex condition that not only significantly affects quality of life, but may be an indicator of systemic disease. Initial assessment includes a detailed history and physical examination and completion of a frequency volume chart to help identify underlying causes, such as sleep disorders, bladder storage disorders, and polyuria. Treatment with alpha-blockers or antimuscarinic medications may help if the underlying cause is determined to be benign prostatic hyperplasia or overactive bladder, respectively. Treatment options for nocturnal polyuria have been limited to behavioral therapy and off-label use of timed diuretics and desmopressin. Desmopressin acetate nasal spray (Noctiva™, Avadel Pharmaceuticals, Chesterfield, MO) was approved by the US Food and Drug Administration in 2017 for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least twice nightly and has shown efficacy in reducing nocturnal voids by ≥50% in up to 49% of patients in clinical trials.

【 授权许可】

Unknown   

【 预 览 】
附件列表
Files Size Format View
RO201910251094475ZK.pdf 380KB PDF download
  文献评价指标  
  下载次数:10次 浏览次数:9次